Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryo Ueda

Showing results (101-110 of 102) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 102 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Brain Communications|October 11, 2021
Evaluation of [<sup>18</sup>F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathiesToshiki Tezuka, Keisuke Takahata, Morinobu Seki, et al.
Pageof 11

Showing results (101-110 of 102) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 102 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Brain Communications|October 11, 2021
Evaluation of [<sup>18</sup>F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathiesToshiki Tezuka, Keisuke Takahata, Morinobu Seki, et al.
Pageof 11